Zobrazeno 1 - 10
of 811
pro vyhledávání: '"Barf, T."'
Autor:
Podoll T; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.) terry.podoll@iv-po.com., Pearson PG; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Kaptein A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Evarts J; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., de Bruin G; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Emmelot-van Hoek M; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., de Jong A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., van Lith B; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Sun H; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Byard S; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Fretland A; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Hoogenboom N; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Barf T; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.)., Slatter JG; Acerta Pharma (a member of the AstraZeneca group), South San Francisco, California (T.P., J.E., A.F., J.G.S.); Acerta Pharma (a member of the AstraZeneca group) Oss, The Netherlands (G.d.B., M.E.-v.H., A.d.J., B.v.L., N.H.); Pearson Pharma Partners, Westlake Village, California (P.G.P.); Covance Laboratories, Madison, Wisconsin (H.S.); Arcinova, Alnwick, United Kingdom (S.B.); and Covalution Holding B.V., Ravenstein, The Netherlands (A.K., T.B.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2023 Jan; Vol. 384 (1), pp. 173-186. Date of Electronic Publication: 2022 Oct 30.
Autor:
van der Wel T; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University & Oncode Institute, Leiden, The Netherlands., Hilhorst R; PamGene International BV, 's-Hertogenbosch, The Netherlands., den Dulk H; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University & Oncode Institute, Leiden, The Netherlands., van den Hooven T; PamGene International BV, 's-Hertogenbosch, The Netherlands., Prins NM; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University & Oncode Institute, Leiden, The Netherlands., Wijnakker JAPM; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University & Oncode Institute, Leiden, The Netherlands., Florea BI; Department of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands., Lenselink EB; Department of Drug Discovery & Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., van Westen GJP; Department of Drug Discovery & Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Ruijtenbeek R; PamGene International BV, 's-Hertogenbosch, The Netherlands., Overkleeft HS; Department of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands., Kaptein A; Covalution Biosciences BV, Ravenstein, The Netherlands., Barf T; Covalution Biosciences BV, Ravenstein, The Netherlands., van der Stelt M; Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University & Oncode Institute, Leiden, The Netherlands. m.van.der.stelt@chem.leidenuniv.nl.
Publikováno v:
Nature communications [Nat Commun] 2020 Jun 25; Vol. 11 (1), pp. 3216. Date of Electronic Publication: 2020 Jun 25.
Autor:
Hoogenboom N; Department of Medicinal Chemistry, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands. Electronic address: n.hoogenboom@acerta-pharma.com., Demont D; Department of Medicinal Chemistry, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., de Zwart E; Department of Medicinal Chemistry, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., Verkaik S; Department of Medicinal Chemistry, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., Emmelot M; Department of Biology and Translational, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., van de Kar B; Department of Biology and Translational, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., Kaptein A; Department of Biology and Translational, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands., Barf T; Department of Medicinal Chemistry, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Nov 15; Vol. 52, pp. 128406. Date of Electronic Publication: 2021 Oct 05.
Autor:
de Bruin G; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands. Electronic address: Gerjan.deBruin@acerta-pharma.com., Demont D; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., de Zwart E; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., Verkaik S; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., Hoogenboom N; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., van de Kar B; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., van Lith B; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., Emmelot-van Hoek M; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., Gulrajani M; Acerta Pharma LLC, 1549 Industrial Road, San Carlos, CA 94070, United States., Covey T; Acerta Pharma LLC, 1549 Industrial Road, San Carlos, CA 94070, United States., Kaptein A; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands., Barf T; Acerta Pharma B.V., Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2020 Jul 15; Vol. 30 (14), pp. 127261. Date of Electronic Publication: 2020 May 13.
Autor:
Mehra, Shefali1 (AUTHOR) shefalimehra@med.miami.edu, Nicholls, Miah2 (AUTHOR) men67@miami.edu, Taylor, Justin1 (AUTHOR) jxt1091@miami.edu
Publikováno v:
International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7516. 15p.
Autor:
Benkhadra, Maria1 (AUTHOR) mbenkhadra@hamad.qa, Fituri, Nuha2 (AUTHOR) nfituri@hamad.qa, Aboukhalaf, Soha2 (AUTHOR) saboukhalaf@hamad.qa, Ghasoub, Rola1 (AUTHOR), Mattar, Mervat3 (AUTHOR) mermattar@kasralainy.edu.eg, Alfarsi, Khalil4 (AUTHOR) khalilf@squ.edu.om, Alshemmari, Salem5 (AUTHOR) salem.alshammari@ku.edu.kw, Yassin, Mohamed A.2,6 (AUTHOR) mbenkhadra@hamad.qa
Publikováno v:
Cancers. Jun2024, Vol. 16 Issue 11, p2079. 16p.
Autor:
Galitzia, Andrea1 (AUTHOR) andrea.galitzia@aslnuoro.it, Maccaferri, Monica2 (AUTHOR) maccaferri.monica@aou.mo.it, Mauro, Francesca Romana3 (AUTHOR) mauro@bce.uniroma1.it, Murru, Roberta4 (AUTHOR) roberta.murru@aob.it, Marasca, Roberto2,5 (AUTHOR) roberto.marasca@unimore.it
Publikováno v:
Cancers. Jun2024, Vol. 16 Issue 11, p1996. 37p.
Autor:
Zhao, Yanan1 (AUTHOR) ynzhao17@mails.jlu.edu.cn, Chakraborty, Praloy1 (AUTHOR) praloy.chakraborty@uhn.ca, Tomassetti, Julianna1 (AUTHOR) juliannatomassetti101@gmail.com, Subha, Tasnia1 (AUTHOR) tasniasubha@outlook.com, Massé, Stéphane1 (AUTHOR) stephane.masse@uhn.ca, Thavendiranathan, Paaladinesh1,2 (AUTHOR) dinesh.thavendiranathan@uhn.ca, Billia, Filio1,2 (AUTHOR) phyllis.billia@uhn.ca, Lai, Patrick F. H.1 (AUTHOR) patrick.lai@uhn.ca, Abdel-Qadir, Husam1,2,3 (AUTHOR) husam.abdel-qadir@uhn.ca, Nanthakumar, Kumaraswamy1 (AUTHOR) kumar.nanthakumar@uhn.ca
Publikováno v:
International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p6207. 18p.
Autor:
Thomas, Colin J.1,2 (AUTHOR) colin.thomas1@pennmedicine.upenn.edu, Carvajal, Veronica2 (AUTHOR), Barta, Stefan K.1,2 (AUTHOR)
Publikováno v:
Cancers. May2024, Vol. 16 Issue 10, p1937. 17p.
Autor:
Wiśniewski, Kamil1 (AUTHOR) bpula@ihit.waw.pl, Puła, Bartosz1 (AUTHOR)
Publikováno v:
International Journal of Molecular Sciences. May2024, Vol. 25 Issue 10, p5246. 12p.